UB Paderborn / Katalog / Suche / in CDI

1 – 16 von 16

Sortiert nach

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice

Frontiers in oncology, 2024, Vol.14, p.1374547-1374547

2024

Link zum Volltext

Verfügbarkeit prüfen

Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID‐19 Outbreak

The oncologist (Dayton, Ohio), 2020-07, Vol.25 (7), p.e1013-e1020

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-05-09: Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-05-09

2020

Link zum Volltext

Verfügbarkeit prüfen

Antiangiogenic strategies in breast cancer management

Critical reviews in oncology/hematology, 2010-10, Vol.76 (1), p.13-35

2010

Link zum Volltext

Verfügbarkeit prüfen

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

Breast cancer research and treatment, 2013-06, Vol.139 (2), p.411-419

2013

Link zum Volltext

Verfügbarkeit prüfen

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

Breast (Edinburgh), 2012-12, Vol.21 (6), p.716-723

2012

Link zum Volltext

Verfügbarkeit prüfen

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma : Pooled analysis of 2 consecutive trials

Cancer, 2007-03, Vol.109 (6), p.1060-1067

2007

Link zum Volltext

Verfügbarkeit prüfen

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Cancer, 2007-03, Vol.109 (6), p.1060-1067

2007

Link zum Volltext

Verfügbarkeit prüfen

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma

Cancer, 2004-08, Vol.101 (4), p.704-712

2004

Link zum Volltext

Verfügbarkeit prüfen

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA)

Annals of the New York Academy of Sciences, 1993-11, Vol.698 (1), p.318-328

1993

Link zum Volltext

Verfügbarkeit prüfen

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Cancer management and research, 2021-01, Vol.13, p.9379-9389

2021

Link zum Volltext

Verfügbarkeit prüfen

Investigation on the role of biallelic variants in VEGF‐C found in a patient affected by Milroy‐like lymphedema

Molecular genetics & genomic medicine, 2020-09, Vol.8 (9), p.e1389-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(14)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)
Japanisch
(1)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice

Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID‐19 Outbreak

Abstract P4-05-09: Molecular differences between high and low tumor mutational burden (TMB) across breast cancer (BC) subtypes

Antiangiogenic strategies in breast cancer management

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer

An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: Results from the Gruppo Oncologico Nord Ovest Randomized Trial

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma : Pooled analysis of 2 consecutive trials

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial

Endocrine therapy of breast cancer. The experience of the Italian Cooperative Group for Chemohormonal Therapy of Early Breast Cancer (GROCTA)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Minor Hepatectomies: Focusing a Blurred Picture: Analysis of the Outcome of 4471 Open Resections in Patients Without Cirrhosis

Stratification of Major Hepatectomies According to Their Outcome: Analysis of 2212 Consecutive Open Resections in Patients Without Cirrhosis

Investigation on the role of biallelic variants in VEGF‐C found in a patient affected by Milroy‐like lymphedema

Suchergebnisse filtern